Echinocandins are a class of antifungal drugs that inhibit the synthesis of β-glucan in the fungal cell wall via noncompetitive inhibition of the enzyme 1,3-β glucan synthase. The class has been dubbed the "penicillin of antifungals," along with the related observation that their targeted inhibition of fungal cell wall assembly produces potent activity against Candida species while sparing mammalian cells that lack β-glucan in their membranes. Chemically they are large cyclic lipopeptides derived from natural pneumocandin scaffolds and subsequently semisynthesized to optimize stability and spectrum. Mechanistically, reduction of β-(1,3)-D-glucan weakens cell wall integrity leading to osmotic instability and death or growth arrest depending on species; activity is generally fungicidal against Candida and fungistatic against Aspergillus. Key pharmacokinetic properties are low oral bioavailability, high plasma protein binding, predominant intravenous administration for licensed agents, variable hepatic metabolism and nonrenal degradation pathways for some members, and distribution primarily into extracellular fluids. Clinically relevant considerations include species-specific MIC ranges, potential for infusion-related reactions, dose adjustments in hepatic impairment for certain agents, and documented drug interaction profiles that are usually less severe than those of many azole antifungals.
![1-[(4R,5R)-4,5-Dihydroxy-L-ornithine]-Echinocandin B (HCl Salt)](https://veeprho.com/wp-content/uploads/2023/12/1-4R-5R-4-5-Dihydroxy-L-ornithine-Echinocandin-B-HCl.png "1-[(4R,5R)-4,5-Dihydroxy-L-ornithine]-Echinocandin B (HCl Salt)")
Parent: Echinocandin
Impurity and related compound control for echinocandin active pharmaceutical ingredients focuses on peptide-related degradants and process-related residuals; common degradant classes include deacylated or desaturated peptide fragments, oxidized side chains (for example methionine sulfoxides), epimers at stereogenic centers, N- and C-terminal cleavage products, dehydrated or anhydro forms, and solvent or reagent residues from semisynthesis. Typical manufacturer specifications for parenteral peptide APIs target individual unspecified impurities at low parts-per-hundred levels, for example individual related substances commonly limited to about 0.1 to 0.5 percent w by w and total impurities often limited to approximately 1.0 percent w by w, with tighter limits applied to specified known toxic degradants; specified impurity limits and acceptance criteria follow ICH Q3A and applicable pharmacopeial monographs and will vary by specific echinocandin (caspofungin, micafungin, anidulafungin) and regulatory filing. Analytical control employs orthogonal methods such as HPLC with charged aerosol or UV detection, LC-MS for degradant identification, and forced degradation studies to define degradation pathways and set shelf life and storage conditions.
Echinocandin drugs are a group of cyclic lipopeptide antifungals that inhibit fungal 1,3-β-glucan synthase, used primarily to treat invasive Candida infections and as therapy or salvage therapy for certain Aspergillus infections.
Examples include caspofungin, micafungin, and anidulafungin; each is a semisynthetic derivative of natural pneumocandin-like precursors with distinct formulation and dosing characteristics.
Most licensed echinocandins are administered intravenously due to poor oral bioavailability; research continues on oral formulations and prodrugs but routine clinical use is predominantly IV.
Echinocandins are generally higher cost than many oral antifungals because of complex semisynthetic manufacture, parenteral formulation and hospital administration; exact expense depends on region, agent, dosing duration and local procurement or reimbursement arrangements.
